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Despite remarkable advances in pharmaceutical drug design, effective chemotherapy options 
for brain and nervous system cancers that demonstrate selective cytotoxicity remain a 
challenge in medicinal chemistry. A recent National Cancer Institute report stated, “over the 
last 30–40 years, the mortality rate for brain and other CNS cancers has remained largely 
unchanged.”1 Current chemotherapeutic options are limited, and typically only provide 6–24 
month survival rates.2 Recently, curcumin has become a pharmaceutical target of interest 
based on its diverse range of biological activity.1 A bioactive metabolite of the rhizome of 
Curcuma longa and the major component of the traditional Indian folk medicine turmeric, 
this diarylheptanoid exhibits anti-cancer, anti-inflammatory, anti-oxidant, and 
chemopreventative properties.3 This naturally occurring metabolite demonstrated apoptotic 
induction and cytotoxicity toward a variety of cancer cell lines, while exhibiting a 
remarkable lack of adverse side effects and no systemic toxicity.4 Recent work has shown 
that curcumin possesses impressive growth inhibition and induction of apoptosis of 
glioblastoma and neuroblastoma cells in vitro, and decreased tumorigenesis in vivo.5 
Unfortunately, its affinity for a wide range of targets, low potency, and unsatisfactory 
pharmacokinetics limits the clinical viability of this biologically versatile natural product.6
Correspondence to: Karen E. Pollok; Brandon L. Ashfeld.
NIH Public Access
Author Manuscript
Bioorg Med Chem Lett. Author manuscript; available in PMC 2014 November 21.
Published in final edited form as:













As a result, a number of groups have focused on the design of curcumin structural analogs to 
optimize specific chemotherapeutic properties. Analog evaluation has primarily fixated on 
the aryl and β-diketone regions, which are considered crucial for activity.6 In contrast, the 
olefins at C1 and C6 are commonly believed to serve as linkers for the aromatic and ketone 
regions, and therefore, significant structural modification of this region has not been studied 
in detail. We chose to target analogs possessing an aryl-substituted tertiary center at C1 or 
C3 and evaluate them for brain and nervous system anticancer activity to glean insight into 
the biological activity of curcumin (Figure 1). Our recently developed titanocene-catalyzed 
multicomponent coupling reactions7 enables rapid access to C1 and C3 aryl-substituted 
analogs 2 and 3 of curcumin, thereby allowing us to strategically design, synthesize, and 
evaluate a diverse array of curcumin-derived arylheptanoid analogs.8
We envisioned that our titanocene-catalyzed multicomponent coupling9 would provide a 
direct route to C1-arylated curcumin analogs through the union of an electron rich arene, 
benzaldehyde derivative, and an iodoalkyne comprised of the C1–C7 carbon chain oxidized 
at C5. In an effort to maintain the enol–OH functionality present in curcumin, we targeted 
secondary alcohol 9 as a mixture of C1 epimers (Scheme 1).
Enantioenriched iodoalkyne 5 was obtained in three steps from known aldehyde 410 using a 
titanium-catalyzed asymmetric propargylation.11 Treatment of 5, arene 6, and aldehyde 7 
with Cp2TiCl2 (5 mol%), PtBu3, Zn, Cs2CO3, and Ac2O provided diarylethynyl methane 8 
in 99% yield.12 Treatment with TBAF liberated the secondary hydroxyl group at C5 to give 
the target alcohol 9 in 83% yield. With alcohol 9 in hand, we sought to reduce the alkyne 
functionality to the corresponding trans olefin in an effort to provide a comparison to the 
curcumin carbon backbone. Thus, treatment of 9 with Me2SiHCl followed by a ruthenium-
catalyzed alkyne hydrosilylation gave the trans-alkene 10.13 This highly convergent strategy 
toward constructing the triarylated curcumin C1–C7 carbon framework ultimately permits 
modular flexibility required for a complete SAR study based on the general structure of 2.
Our synthesis of the C3-arylated curcumin analogs began with construction of the C4–C7 
fragment for the titanocene-catalyzed multicomponent coupling (Scheme 2). Esterification 
of commercially available acid 11 followed by silylation of the phenol and treatment with 
DIBAL-H gave aldehyde 12 in 64% yield over three steps.14 A Corey-Fuchs alkynylation15 
in which the lithium acetylide was quenched with I2 yielded iodoalkyne 13 in 69% yield.16 
This establishes a simple and reliable route toward this curcuminoid fragment.
With our C4–C7 fragment in hand, we turned our attention toward the crucial titanocene-
catalyzed multicomponent coupling. Thus, treatment of iodoalkyne 13, aldehyde 14, and 
silyl enol ether 1518 with Cp2TiCl2 (2 mol %), (4-MeOC6H4)3P, Zn(0), and Ac2O gave a 
mixture of β-aryl ketones 16a and 16b in which the TMS-phenol protodesilylation proved 
remarkably facile (Scheme 3). Silylation of the resulting free phenol in 16a gave ketone 16c 
in 91% yield. Diastereoselective ketone reduction using Corey’s CBS reagent provided 
alcohol 17 in 77% yield as a 1:1 mixture of diastereomers in 92% ee each.19
Structural-activity relationships of compounds were evaluated in human U87 MG GBM and 
neuroblastoma (NB) SK-N-SH and SK-N-FI cells. Cells were exposed to increasing 
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concentrations of compounds 9, 10, 16a–c, or 17. Cell growth was determined using a 
methylene blue staining assay that measures cell mass and correlates with cell number 
(Figure 2).20 Both 16a and 16b significantly affected growth in the low µM range in U87 
GBM cells as illustrated by the IC50 values of 16a, 16b and curcumin21 (Table 1, entries 1–
8). Since p53 mutations can be found in a variety of cancers, including GBM and NB, we 
evaluated the dependency of compound efficacy on p53 status.22 U87MG cells (parental p53 
wild type, vector control, and p53 knockdown) had identical sensitivity profiles, indicating 
that 16a and 16b can block growth independent of p53 expression (Figure 3, A and B). 
Additionally, effect on cell growth was not dependent on functional p53 in either SK-N-SH 
(wild type p53) or SK-N-FI (mutant p53) neuroblastoma cells, as both were sensitive to 16a 
and 16b (Figure 3, C and D; Table 1, entries 9–16). Given that normal tissue toxicity can be 
a limiting factor in many anticancer therapies, we screened for compound effect on normal 
hematopoietic progenitor cells using colony-forming unit assays.23 Human CD34+ cells 
isolated from umbilical cord blood served as a fresh source of human progenitor cells and 
were treated with doses of the most active compounds, 16a and 16b and 10, for purposes of 
comparison. The assay was performed at concentrations of these compounds that had 
minimal effect on U87 MG cell growth (0.3 & 3.0 µM) and doses that significantly affected 
the growth of U87 MG cells (30 µM). As illustrated in Figure 4, compound-mediated 
toxicity was minimal over a 0.3–30 µM dose-range of 16a and 16b. At 30 µM, treatment 
with 16b led to a 20%–25% decrease in the number of colonies. These data indicate that, at 
least in vitro, compound-mediated toxicity to hematopoietic cells was not pronounced.
In summary, we have established a universal and direct strategy for the assembly of 
curcumin analogs using a transition metal-catalyzed multicomponent coupling strategy. This 
highly convergent approach enables the rapid evaluation of structural analogs based on this 
biologically active natural product. A series of curcumin-based diarylheptanoid analogs 
were synthesized and evaluated for anti-glioblastoma and anti-neuroblastoma properties. 
The potency of the 16a and 16b was only slightly less than that of curcumin and was still in 
the low micromolar range, These results enabled us to identify a number of lead compounds 
that provides a foundation toward identifying diarylheptanoid analogs which are cytotoxic 
against brain and peripheral nervous system cancers and have improved metabolic and 
pharmacokinetic profiles in vivo. Further investigation of individual diastereomers, the 
application of our design strategy and subsequent evaluation of curcumin-based analogs is 
currently underway and will be reported in due course.
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Design and synthesis of curcumin analogs.
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Dose-related decreases in cell survival of U87 MG GBM cells by curcumin analogs. Cells 
were exposed in triplicate to vehicle or increasing concentrations of compounds 9, 10, 16a–
c, 17, or curcumin and survival was measured at 5 days post-exposure.17 *p < 0.05 vs. 
media control, Dunnett’s multiple comparisons test.
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Dose-related decreases in cell survival of glioblastoma and neuroblastoma cells irrespective 
of p53 status. Cells were exposed in triplicate to vehicle or increasing concentrations of 
compound and survival was measured at 5 days post-exposure.17 * p < 0.05, 16a and 16b 
versus vehicle control. (A) Effect of 16a and (B) 16b on U87 parental wild type p53, U87 
vector control (U87gfpcontrol), and cells with knock down of p53 (U87 shp53) were 
determined as described above. (C and D) Dose response curves of wild type 53 NB (SK-N-
SH) and mutant p53 NB (SK-N-FI) cells to 16a and 16b. *p < 0.05 vs. media control, 
Dunnett’s multiple comparisons test.
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Effect of select compounds on human progenitor cell growth. Human CD34+ cells were 
exposed in triplicate to 0.3–30 µM of compounds 16a, 16b, or 10. Progenitor cell frequency 
was determined after 14 days. *p < 0.05 vs. media control, Dunnett’s multiple comparisons 
test (16b at 30 µM).
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Table 1
Potency of curcumin derivatives in decreasing glioblastoma cell and neuroblastoma cell survival.a
Entry Tested compounds IC50 (µM)
Glioblastoma Cell Lines




5 U87-MG sh-gfp 16a 7.0
6 16b 6.9
7 U87-MG sh-p53 16a 7.0
8 16b 7.0
Neuroblastoma Cells









IC50 values for each compound were determined using CalcuSyn Software (Biosoft, Cambridge, UK).
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